Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study

Area of Science:

• Neuroscience
• Psychopharmacology

Background:

• Depression is linked to changes in brain structures like the hippocampus and amygdala.
• Ketamine has shown potential in reversing these structural changes and alleviating depressive symptoms.

Purpose of the Study:

• To investigate how psilocybin affects neurotransmission in the limbic system compared to ketamine.
• To explore the neurobiological underpinnings of psilocybin's potential antidepressant effects.

Main Methods:

• Microdialysis in rats to measure neurotransmitter release (dopamine, serotonin, glutamate, GABA, ACh).
• Assessment of receptor density changes (D2, 5-HT1A, 5-HT2A) in the nucleus accumbens and hippocampus.
• Open field test to evaluate anxiolytic effects.

Main Results:

• Both psilocybin and ketamine increased dopamine and serotonin release in the nucleus accumbens.
• Both substances altered glutamate and GABA release across key brain regions and increased acetylcholine in the hippocampus.
• Long-lasting changes in receptor density were observed, alongside a significant anxiolytic effect of psilocybin.

Conclusions:

• Psilocybin modulates neurotransmission in the limbic system, similar to ketamine.
• These neurobiological effects provide a basis for psilocybin's anxiolytic and potential antidepressant actions.
• Findings support psilocybin's therapeutic potential for depression and anxiety disorders.